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Abstract
Genetic variants altering cis-regulation of normal gene expression (cis-eQTLs) have been extensively mapped in human cells
and tissues, but the extent by which controlled, environmental perturbation influences cis-eQTLs is unclear. We carried out
large-scale induction experiments using primary human bone cells derived from unrelated donors of Swedish origin treated
with 18 different stimuli (7 treatments and 2 controls, each assessed at 2 time points). The treatments with the largest
impact on the transcriptome, verified on two independent expression arrays, included BMP-2 (t=2h), dexamethasone (DEX)
(t=24h), and PGE2 (t=24h). Using these treatments and control, we performed expression profiling for 18,144 RefSeq
transcripts on biological replicates of the complete study cohort of 113 individuals (ntotal=782) and combined it with
genome-wide SNP-genotyping data in order to map treatment-specific cis-eQTLs (defined as SNPs located within the gene
6250 kb). We found that 93% of cis-eQTLs at 1% FDR were observed in at least one additional treatment, and in fact, on
average, only 1.4% of the cis-eQTLs were considered as treatment-specific at high confidence. The relative invariability of cis-
regulation following perturbation was reiterated independently by genome-wide allelic expression tests where only a small
proportion of variance could be attributed to treatment. Treatment-specific cis-regulatory effects were, however, 2- to 6-fold
more abundant among differently expressed genes upon treatment. We further followed-up and validated the DEX–specific
cis-regulation of the MYO6 and TNC loci and found top cis-regulatory variants located 180 kb and 250 kb upstream of the
transcription start sites, respectively. Our results suggest that, as opposed to tissue-specificity of cis-eQTLs, the interactions
between cellular environment and cis-variants are relatively rare (,1.5%), but that detection of such specific interactions can
be achieved by a combination of functional genomic approaches as described here.
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Introduction
The genetic contribution to population variation in cis-
regulation of gene expression has been well studied in expression
QTL (eQTL) studies where genome-wide expression profiles in
cells or tissues of interest are statistically linked to sequence
variants, known as ‘‘expression SNPs’’ or eSNPs. Following the
pioneering of mapping eQTLs using Epstein-Barr virus trans-
formed lymphoblastoid cell lines (LCLs) [1] such as those analyzed
in the HapMap project [2,3], various primary cells [4–8] and
complex tissues [5,8–10] have been used for the identification of
cis-regulatory variants. These eQTL studies have all been able to
show a strong effect of common cis-variants on gene expression as
compared to trans-effects that are more difficult to detect due to
smaller effect sizes [7]. More recently, eQTL studies have included
multiple cell types from the same study population where results
have pointed towards a substantial proportion of cis-effects being
reproducible across different cell types [11]. However, although a
large proportion of the cis-effects seem to be cell-type invariant,
others may act in a cell-type specific manner [4,11].
Environmental factors influence gene expression, and undoubt-
edly interaction between sequence variants and environmental
stimuli represents a critical step to cellular development and
disease pathogenesis. Modeling gene-environment interactions in a
clinical setting is challenging, but eQTL mapping may represent
an excellent model for identifying these important interactions that
impact phenotype. Smirnov et al [12] studied inter-individual
differences in expression in response to radiation in LCLs and
found that most regulators influencing radiation-induced gene
expression act in trans with very few cis-regulatory effects.
PLoS Genetics | www.plosgenetics.org 1 January 2011 | Volume 7 | Issue 1 | e1001279Similarly, in a recent report studying the effect of pro-
inflammatory oxidized phospholipids on global gene expression
in human primary endothelial cell lines, the majority of the
regulated transcripts were shown to be influenced by trans-acting
loci [13].
In an attempt to elucidate the impact of non-genetic,
experimental factors such as growth conditions on eQTL mapping
in cultured cells, we previously studied multiple primary cell lines
derived independently from the same individual, and assessed the
replicability of cis- versus trans-associations using these biological
replicates. We found that cis-eQTLs are highly reproducible across
biological replicates, as compared to trans-eQTLs that showed
much lower than expected overlap across replicates [7]. Clearly,
larger sample sizes are needed in order to find SNPs with true trans
regulatory effects on gene expression.
To explore the impact of environmental perturbation on cis-
regulation (defined here as variants located within the gene or in a
6250kb window flanking the gene) of human gene expression, we
performed large-scale induction experiments using human prima-
ry osteoblasts (HOb) from a population panel described previously
[7,14]. Environmental stimuli included growth factors [15,16],
cytokines [17,18] and hormones [19–21], all with previous known
effects on the osteoblast transcriptome. We verified that the
response upon treatment was robust before proceeding with cis-
eQTL analysis. In addition to standard eQTL mapping, we
applied an alternative approach with improved sensitivity for
mapping cis-regulatory variants based on the measurement of
allele-specific expression (AE) that directly demonstrates that a
variant acts in cis [11,22,23]. We employed the Illumina
HumanOmni1-Quad BeadChip for global assessment of AE - an
approach based on the quantitative assessment of allele ratios in
expressed heterozygous SNPs in RNA samples, which are then
normalized to corresponding genomic DNA heterozygote ratios.
An outline of the study is presented in Figure 1. Using these
approaches we find that the cis-regulatory landscape within a cell is
very stable, with only a small proportion of the identified cis-
eQTLs being specific to environmental stimuli.
Results
Differential gene expression upon environmental
perturbation
Human osteoblast-like cells (HOb) derived from 113 unrelated
Swedish donors, each with independently derived primary cell
lines (n=3), were cultured under 18 different conditions: seven
different treatments (BMP-2, dexamethasone (DEX), IGF1, PTH,
PGE2, TNFa, 1.25VitD3) and two controls, each at two time
points (2h and 24h, respectively). To identify those conditions that
most clearly influenced global gene expression, we first performed
a pilot study, assessing the response of each treatment on gene
expression upon treatment in three biological replicates for one
individual using Affymetrix GeneChip U133+2 arrays. In general,
all treatments demonstrated significantly more genes that were up-
or down-regulated after 24h exposure than at the earlier time
point (FDR adjusted P value,0.05 and Fold change .2)
(Figure 2A and Figure S1A). Based on both magnitude and
biological relevance of regulated genes, BMP-2, DEX and PGE2
were chosen for the subsequent global analysis of the effect of
environmental perturbation on cis-regulation. DEX and BMP-2
treatment regulate the expression of several immediate-early (2h
exposure) and late (24h exposure) genes and pathways related to
bone cell function as previously described [14]. For instance, upon
stimulation with BMP-2 for 2h, a large number of negative
regulators are up-regulated including the inhibitory Smads
(SMAD6 and SMAD7) and the BMP inhibitor, Noggin. In DEX-
treated samples, the IGF1 signaling pathway is one of the top
canonical signaling pathways down-regulated following stimula-
tion. We further analyzed the genes regulated by PGE2 and found
them significantly associated with skeletal development and
function including growth (P=3610
24, Fisher’s exact test),
differentiation (P=3610
24, Fisher’s exact test) and formation of
bone cells (P=9610
24, Fisher’s exact test).
To verify that the observed responses upon treatment were
robust across expression platforms, we profiled one additional
individual using Illumina HumanRef8 v2 BeadChips and again
found that stimulation by DEX, BMP-2 and PGE2 resulted in the
most striking gene expression changes (Figure 2B) with modest to
weak effects of the remaining treatments (Figure S1B). The
proportions of differentially expressed genes (1-pi0) among all
tested genes for the three treatments are presented in Table S1. In
addition, complete lists of response genes upon treatment are
shown in Tables S2, S3, S4. We have previously validated
response genes upon DEX and BMP-2 treatment [14] by real-time
RT-PCR, and upon PGE2 stimulation in this study, and in all
cases the direction of effect was the same (Figure S2).
We then obtained whole genome expression profiles from the
cultured primary cells that were untreated (t=24h, N=94) and
treated with DEX (t=24h, N=107), BMP-2 (t=2h, N=101),
PGE2 (t=24h, N=100), each with at least two biological
replicates, using Illumina HumanRef8 v2 arrays. For each
individual, we averaged the normalized expression scores across
biological replicates to obtain a single measure for each of the
18,144 genes included on the array.
We further studied whether responses upon DEX, BMP-2 and
PGE2 treatments seen in a single sample as described above using
Affymetrix GeneChips accurately represented a general effect in
the study population. Approximately 13,000 RefSeq transcripts
overlapped the two studies and the expression response for each
treatment from the different studies was used in a correlation
analysis (median log2 fold change was used as an estimate of the
general effect in the study population). We found strong
correlations (r=0.5–0.6) of expression changes by individual
Author Summary
Population variation in normal gene expression has been
convincingly shown to be under strong genetic control
where the main genetic variants are located within close
proximity to the gene itself (so called cis-acting). However,
the extent to which controlled, environmental stimuli
influences cis-regulation of gene expression is unclear.
Here, we combine different functional genomic approach-
es and examine the role of common genetic variants on
induced gene expression in a population panel of primary
human cells derived from ,100 unrelated donors treated
under multiple conditions. Using these approaches, we
find that the interaction between cellular environment and
cis-variants are relatively rare, with only a small proportion
of the identified genetic variants being specific to
treatment. However, although treatment-specific genetic
regulation of gene expression seems to be infrequent, we
prove its existence by thorough validation of treatment-
specific effects of the glucocorticoid-specific regulation of
TNC expression. Taken together, these findings indicate
that the regulatory landscape within a cell is very stable
but, by combining functional genomic tools gene-envi-
ronmental interactions of clinical importance, can be
detected and possibly used as biomarkers in future
pharmacogenomic studies.
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selected treatments robustly impact the expression profiles in the
study population.
Mapping of cis-eQTLs upon perturbation
The samples included here have previously been genotyped
using the Illumina Hap550K arrays and were included in our
recent work of cis-eQTL analysis focused on the untreated control
samples from the same study population [7]. All probes
overlapping a SNP (dbSNP 126) were removed as previously
described resulting in ,17,000 probes included in the eQTL
analyses. The conditioned expression traits were used as
dependent variables in linear regression models and adjusted for
sex and year of birth. Our analysis focused on cis-regulatory
variants defined as SNPs (N=388,946) located in a 250kb window
flanking the target transcript [7].
Summary statistics from the cis-eQTL analyses are presented in
Table 1 and in Figure S4 using all samples (n=94–101) and in
Table S5 separating the biological replicates in identical samples
across treatments (n=80). Characteristics of all significant,
independent cis-variants (5% FDR) including distance to tran-
scription start site (TSS) and SNP category (i.e. intronic, 39UTR,
coding etc) are presented in Table S6 and Figure S5. At all three
significance levels (Bonferroni P,3.5610
28, 1% FDR, and 5%
FDR), we identified on average ,40% more cis-eQTLs in induced
samples as compared to the untreated controls. However, when we
compared top ranked cis-eQTLs between treatments we found a
high overlap of significant associations across treatments (Figure 3).
Despite clear global effects of each treatment to expression
profiles, genes under genetic cis-regulatory component demon-
strate very similar dependence on local variants. For example,
93% of cis-eQTLs identified in DEX treated samples at 1% FDR
(P,2.5610
25) are observed in at least one other condition at a
slightly less stringent P-value threshold of P=5610
24. The
overlap changes only slightly when considering independent
signals (87% versus 93%). This degree of overlap across treatment
groups is similar to the proportion of shared cis-eQTLs between
two biological replicates, as previously described [7]. Similarly,
when we restrict analysis to significant cis-eQTLs (1% FDR) in
DEX-treated samples, we note strong enrichments of low P-values
in the eQTL analysis for both of the other treatments (BMP-2,
PGE2) and in the untreated control samples, confirming that the
vast majority of observed eQTL associations are observed
regardless of experimental condition (Figure S6). We then asked
whether the shared cis-eQTLs across treatments are for genes that
significantly respond to each treatment or if they are expressed,
but not differentially expressed. We classified the genes as
responders (significant .1.5-fold difference in expression upon
induction) and non-responders based on the pilot data (Table S2,
S3, S4) but found no difference in the proportion of overlapped cis-
eQTLs between the two lists of genes.
We defined high-confidence environmental-specific cis-eQTLs
as being 1) significant in one treatment at 1% FDR or 5% FDR,
respectively, and 2) non-significant (P.0.05) in all three remaining
conditions. As expected based on the results from the initial
analysis described above, treatment-specific cis-eQTLs were found
to be rare. At 1% FDR, we identified on average 1.4% treatment-
specific cis-eQTLs, representing only a slight excess to the
expected false discovery rate (Table 2). When restricting to
independent cis-eQTLs only, the treatment specificity at 1% FDR
was increased to ,2.5% (all treatment-specific cis-eQTLs at 5%
FDR are presented in Table S7, S8, S9). The identified high-
confidence cis-eQTLs at 5% FDR corresponded to 72–143 genes
per treatment group (Table 2) where we found evidence of a ,2-
fold enrichment of treatment-specific expression pattern for the
DEX-specific genes harboring an eQTL, than expected by chance
(binomial P,0.05). No such enrichment was seen for the BMP-2
or PGE2 specific associations.
We further analyzed the genes harboring treatment-specific cis-
eQTLs for enrichment in biological processes or pathways using
the Ingenuity Pathway Analysis software and the results are
presented in Table S10. Interestingly, the top mapped canonical
•Discovery: Affymetrix U133+2 x 14 
conditions
￿Validation: Illumina Ref8 x 14 
conditions, qRT-PCR, pathway 
analysis
Response survey
￿Discovery: Illumina Ref8 x 4 
conditions
￿Validation: biological replicates, 
qRT-PCR, seq-based allelic expression 
(AE) analysis
cis-eQTL mapping
￿Discovery: Illumina humanOmni1-
AE test x 4 conditions
￿Validation: biological replicates,  
seq-based AE analysis
cis-expression
variation
Figure 1. Study outline.
doi:10.1371/journal.pgen.1001279.g001
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inhibitory factor)-mediated glucocorticoid regulation (P=7.43E-
04, Fisher’s exact test).
We also analyzed the data sets jointly by fitting a linear mixed
model where the treatment*SNP interaction term was included
and we found similar proportions as above; i.e. at 5% FDR we
found a total of 853 cis-eQTLs interacting with any treatment
compared to 932 at similar FDR using the approach described
above (Table S11).
We then sought to validate our top high-confidence DEX-
specific cis-eQTLs using low-throughput sequencing-based AE
assessment [24,25] in samples heterozygous for 1) the top cis-eSNP
and 2) an intragenic exonic marker either included on the Illumina
Hap550K array or imputed from the HapMapII panel. We
selected the top five (MYO6, CDSN, ZNF480, LSM16, TMBIM1)
DEX-specific genes (Table 3) where the expression levels were
detectable by RT-PCR. CA2 was excluded due to absence of an
exonic marker, and PLEKHA6 and USP10 were excluded due to
undetected expression in BMP-2 and PGE2 treated samples,
respectively. Of the five selected genes, one failed in sequencing
reaction (CDSN). Of the remaining four genes we were able to
successfully validate treatment specific cis-regulation of the MYO6
locus (Figure 4 and Table S12). Specifically, DEX-treated samples
heterozygous for the top eSNP from the cis-eQTL analysis
(rs646967; DEX eQTL P=8.8610
210, BMP-2 eQTL P=0.8,
PGE2 eQTL P=0.06; Figure 4A) showed allele-specific expression
revealed by differences in RNA (cDNA) allele ratios at the marker
heterozygous site. The normalized allele ratio within each DEX-
treated sample deviated greater than 2SD from the corresponding
BMP-2, PGE2, and genomic DNA heterozygote ratio, respective-
ly, and we found an overall significant difference in mean |D het
ratio| between treatments (rs12606; |D het ratio|DEX=
0.5260.26 and |D het ratio|BMP-2+PGE2=0.0460.02; P=
2.7610
24, t-test; Figure 4B).
We fine-mapped the candidate region upstream of the MYO6
gene by including imputed, untyped HapMapII SNPs and found
the rs584677 SNP, located ,160kb upstream of the TSS, to have
the strongest effect on MYO6 expression (Figure 4C).
Global impact of perturbation on cis-regulation
To directly investigate the impact of environmental perturba-
tion to allelic cis-regulation in primary cells, we carried out an
independent AE assessment in a subset of five randomly selected
samples included in the eQTL study. This was achieved by
Figure 2. Global response on gene expression upon environmental perturbation. The significance of the treatment-induced effects at two
time points, 2h (left panel)and 24h (right panel), on global gene expression assessed by AffymetrixU133+2 arrays (A) and IlluminaRef8 beadarrays (B)
in two individuals, respectively, was determined by the Cyber-t test using three biological replicates in BMP-2 (top), DEX (middle) and PGE2 (bottom)
treated versus control samples, respectively. The results from the statistical tests are combined with the magnitude of the change in gene expression
following perturbation and visualized in Volcano plots with significance (2log10 P value) versus fold change (log2) on the y – and x-axes,
respectively. Lines indicate genes whose expression levels were significantly (FDR adjusted P,0.05) changed more than 2-fold.
doi:10.1371/journal.pgen.1001279.g002
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regulation in a genome-wide manner as we described recently
[26]. The genome-wide AE test was carried out on Illumina
HumanOmni1-Quad genotyping chips by interrogating differenc-
es in RNA (cDNA) allele ratios at heterozygous sites across
primary transcripts normalized to genomic DNA allele ratios from
the same individual. All four cell-culture conditions (DEX, BMP-2,
PGE2 and untreated control) were employed in the experiment
with the DEX treatment carried out in duplicate, resulting in a
total of 25 samples from five individuals included in the analysis.
We verified that these newly cultured cells responded to each
treatment as expected (Table S13, see Methods). A duplicate DEX
and PGE2 sample failed for one individual leaving a total of 23 AE
profiles for analysis. The cDNA data at each heterozygous site
were subjected to expression (signal intensity) and allele resolution
filters [26], respectively, along with a novel method for
normalization of signal intensity induced biases in allele ratio
estimates (see Methods).
Initially, we looked for convergence of the AE data with our
cis-eQTL data. Using five individuals we did not have power to
independently map cis-rSNPs [26], therefore we focused on
samples heterozygous for significant treatment-specific cis-eSNPs
(defined as being significant in one treatment at 5% FDR and
non-significant, P.0.05, in all three remaining conditions). In
total, 162/485 genes (Table S14) with treatment-specific cis-
regulation from the eQTL study were informative for AE test, i.e.
at least one out of five samples being heterozygous for a cis-eSNP
and with the region being robustly expressed. We then used
windows of three consecutive heterozygous SNPs (at least three of
four informative SNPs above signal threshold in each sample) to
detect differential allelic expression, defined as an average |D het
ratio|.0.05 (corresponding to 1.2-fold difference between alleles)
among SNPs showing empirical probability of P,0.05 (see
Methods).
Of the 162 tested regions, evidence of a cis-regulatory effect
was independently confirmed for 73 (45%) genes (Table S14).
Figure 3. Overlap of significant cis-eQTLs across treatment. Top 3000 cis-eQTLs per treatment (FDR,1%) are visualized in a Venn diagram
showing the different levels of sharing across treatment.
doi:10.1371/journal.pgen.1001279.g003
Table 1. Summary of results from conditioned cis-eQTL analysis in primary cells.
Untreated
(n=94)
DEX
(n=101)
BMP-2
(n=96)
PGE2
(n=100)
No of SNPs 380,547 380,763 380,069 380,469
No of tests 1,404,011 1,411,793 1,409,707 1,411,346
No of cis-eQTLs:
All/Independent/Genes
P,3.5610
28 994/233/232 1201/283/282 1409/321/320 1532/356/353
FDR 0.01 2931/682/667 3485/715/692 4416/895/858 4556/878/846
FDR 0.05 4937/1121/1062 5899/1281/1206 7314/1571/1451 7550/1571/1449
doi:10.1371/journal.pgen.1001279.t001
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effects for only a minority (5 of 73 loci, 7%). For the remaining
68 loci (93%), allele-specific expression was observable across
treatments (Table S14). The five validated treatment-specific cis-
eSNPs were shown to have a greater effect on induced gene
expression indicated by differences in fold change (AA versus
BB) than the 68 treatment-independent loci (Figure S7).
Next, we used our AE data set to assess the global impact of
treatment in allelic cis-regulation by measuring AE differences
within (for duplicate measurements used in the case of DEX) or
between treatments in one individual or across samples. The
genome-wide profiles of treatment induced allelic cis-variation
measured the difference of average allele-ratios [mean(|D het
ratio|test2|D het ratio|ref)] using windows of three consecutive
heterozygous SNPs in robustly expressed RefSeq regions (at least
three of four informative SNPs above signal threshold in both
samples). Each treatment (‘‘test’’) was correlated to the same DEX
(‘‘reference’’) sample and only windows expressed in all treatments
were used for within individual comparisons. Treatment explained
,10–15% of variance of AE within an individual (r=0.87–0.89
DEX versus DEX, r=0.77–0.79 DEX versus other treatment)
(Figure 5A). In contrast, the variance of allelic expression among
individuals was considerably higher (average r=0.4), which
eliminated any observable difference within (Figure 5B) or
between treatments (Figure 5C). Overall, these results reiterate
the relative stability of allelic cis-regulation upon environmental
perturbation within a cell type as observed in our eQTL survey as
well as heritability of AE phenotypes observed earlier by us [26]
and others [11].
Finally, we explored the possibility of identifying loci accounting
for the 10–15% higher variance in cis-regulation observed upon
perturbation by observing outliers in treatment comparisons
within samples. We used three SNP windows where all
measurement points consistently showed either lower or higher
deviation from equal expression in reference (DEX) versus test
samples (BMP-2, PGE2 or untreated control), with 40K window
pairs available on average. Genome-wide distribution of pair-wise
differences allowed us to assign a probability (empirical signifi-
cance) for observing three consecutive SNPs with a certain degree
of directional difference (consistently greater or smaller deviation
from equal expression in consecutive SNPs) between reference and
test sample. On average, window pairs reaching permutation
significance of 0.05 or lower (1.8% on average) were further
assessed to look for genes with DEX-specific allelic expression
differences. We observed 16–84 genes (at 12–25% FDR, see
Methods) per sample (Table S15) where DEX treatment
consistently differed from all three other cell culture conditions
Table 2. High-confidence treatment-specific cis-eQTLs.
No of treatment-specific cis-eQTLs:
All/Independent/Genes
P,3.5610
28 FDR 0.01 FDR 0.05
Untreated 1/0/0 11/6/6 106/77/72
DEX 7/3/3 44/25/25 243/122/121
BMP-2 3/1/1 73/34/33 294/150/143
PGE2 4/1/1 58/19/19 289/140/134
doi:10.1371/journal.pgen.1001279.t002
Table 3. Top high-confidence treatment specific cis-eQTLs.
DEX-specific BMP-2-specific PGE2-specific
Gene SNP eQTL P Gene SNP eQTL P Gene SNP eQTL P
MYO6 rs646967 8.8E-10 HSPA2 rs10498516 8.5E-9 CSMD1 rs11782360 1.3E-12
CA2 rs10504814 1.0E-9 SMARCD2 rs2665840 4.9E-7 GJA4 rs2093880 9.3E-08
PLEKHA6 rs17334002 1.5E-8 SPSB1 rs2071931 6.5E-7 SPINK4 rs3860974 1.7E-07
CDSN rs3873334 3.8E-7 RIOK2 rs2544771 8.0E-7 MGC39715 rs12680064 2.2E-06
USP10 rs16974016 1.9E-6 CCL15 rs1634508 9.4E-7 SIRT6 rs3760905 2.2E-06
ZNF480 rs321930 3.8E-6 TTLL11 rs10818589 1.4E-6 GLP2R rs2277689 4.4E-06
LSM16 rs6495119 4.0E-6 ZNF354A rs11743893 1.6E-6 SYTL2 rs290198 4.5E-06
TMBIM1 rs992157 5.2E-6 NR2C2 rs9816383 1.7E-6 LPIN2 rs661767 4.7E-06
IFT74 rs4878149 6.6E-6 C21orf6 rs2832057 1.8E-6 STARD3 rs1877031 5.2E-06
TM4SF11 rs2046532 7.9E-6 COPB2 rs9289573 3.1E-6 PCDH18 rs1320342 5.6E-06
OR1D4 rs2469798 8.9E-6 C14orf50 rs10134770 3.2E-6 KLRK1 rs2734565 8.7E-06
FLJ32569 rs17433088 9.4E-6 OR5T3 rs2512950 3.9E-6 RGS2 rs7415619 8.9E-06
MAGI2 rs3779317 1.0E-5 ABCG4 rs2511841 5.0E-6 BLVRA rs849165 1.0E-05
WDR66 rs895959 1.6E-5 C9orf106 rs3928291 6.3E-6 SORCS3 rs10786828 1.1E-05
PACS1 rs3741370 1.6E-5 ETV2 rs2312305 7.4E-6 IFI44L rs1033999 1.8E-05
RNF190 rs7226286 1.6E-5 KIAA0133 rs2295625 8.2E-6 SULT1E1 rs1354360 2.1E-05
OGFOD2 rs883263 1.7E-5 DTWD2 rs11740134 8.9E-6 BLOC1S3 rs8111069 2.2E-05
SEMA3E rs1524332 1.8E-5 HS747E2A rs1997719 9.3E-6 HSPA4 rs3885730 2.2E-05
ZNF513 rs780090 2.0E-5 COMMD10 rs4283832 1.1E-5 DYNC1I2 rs6752812 2.2E-05
NRM rs6911628 2.0E-5 SOX8 rs7187700 1.2E-5 TNFSF11 rs9533108 2.4E-05
doi:10.1371/journal.pgen.1001279.t003
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mental perturbation. Notably, these genes were 2.3–6.2-fold more
common among the DEX response genes (significant .1.5-fold
difference in expression upon DEX induction) (Table S2 and S15)
than expected by chance (binomial P,0.05 for each sample).
These results suggest that specific interaction of cis-regulatory
sequences with the environment can be directly identified in vivo by
genome-wide AE measurements.
Figure 4. DEX–specific cis-regulation of MYO6 expression. (A) The rs646967 SNP located upstream of the MYO6 gene was shown to be
strongly associated with MYO6 expression in DEX-treated cells (top left) with no effect in BMP-2 (top middle), PGE-2 (top right) or untreated samples
(data not shown). Expression scores from Illumina Ref8 BeadArrays for each individual are averaged from two biological replicates and shown as red
circles and the regression line from linear regression model is indicated with blue dashes. (B) The treatment-specific effect of cis-regulation of MYO6
expression was validated by sequencing-based allelic expression test in four samples heterozygous for both the rs646967 cis-eSNP and for the
intragenic rs12606 marker. Normalized rs12606 heterozygote allele ratios of RNA samples from DEX (24h), BMP-2 (2h) and PGE2 (24h) treated cells
were compared within and between samples and data are presented as mean 6 SD of three technical replicates. Significant P-value is obtained from
t-test comparing |D het ratio| in DEX versus BMP-2 and PGE2 samples. (C) The cis-eQTL analysis of the MYO6 region was expanded by the inclusion of
imputed untyped HapMapII SNPs. The P-values from the linear regression analysis represented as 2log10(P-value) are shown as vertical bars with a
horizontal line indicating a cutoff of P=10
24. The rs584677 SNP, marked with an arrow, located ,160kb upstream of the transcription start site
showed the most significant association with MYO6 expression.
doi:10.1371/journal.pgen.1001279.g004
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PLoS Genetics | www.plosgenetics.org 7 January 2011 | Volume 7 | Issue 1 | e1001279Figure 5. Global effect of environmental perturbation on allelic cis-regulation. (A) Treatment specific changes in AE within an individual
(left panel). A total of 224,944 expressed three SNP windows measured in both DEX samples and in three other conditions were available across four
individuals. The x-axis shows magnitude of AE (|Dhet ratio|) in reference DEX window correlated against magnitude of AE observed in independent
DEX measurement on y-axis, against AE observed in BMP-2 treatment, against PBS or PGE2. The Pearson correlation (R) for each pair-wise comparison
is shown and demonstrates that treatment contributes slightly to differential cis-regulation observed by the genome-wide AE test. (B) Interindividual,
treatment independent variation in allelic expression (upper right panel). A total of 27,836 identical informative three SNP windows were measured
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(TNC) locus—a corticosteroid pharmacogenetic
candidate locus
We followed-up and validated our top DEX-dependent cis-
regulated locus, the Tenascin-C (TNC) locus, identified in the
global AE test (Figure 6A) using low-throughput methods in an
extended set of samples as well as at different time points (t=2h
and t=24h). We were able to successfully confirm the treatment-
specific effect after 24h but no difference in AE was seen after 2h
(Figure 6B) indicating a time-dependent effect of the gene
regulation.
We extended our cis-eQTL analysis in DEX-treated samples by
including imputed HapMapII SNPs in order to fine-map the
association and found the top SNP (rs7850103, P=2610
27)
located ,250 kb upstream of the TSS (Figure 6C). Further real-
time RT-PCR experiments confirmed that down-regulation of
TNC expression by DEX is genotype-dependent (Figure S8). We
then asked whether DEX-dependent heritable cis-regulation of
TNC expression could underlie the difference in inhaled
corticosteroid treatment response in the treatment of childhood
asthma. We chose asthma as a clinical model given that (1) inhaled
corticosteroids represent the most commonly prescribed and
efficacious asthma controller medication; (2) clinical response to
inhaled corticosteroids in asthma is variable between subjects; and
(3) TNC expression is known to be increased in lung tissue of
asthmatics, which is modulated by corticosteroid treatment [27].
We tested six SNPs located in our candidate region in children
with mild-to-moderate persistent asthma enrolled in a multicenter,
randomized, placebo-controlled trial of inhaled anti-inflammatory
medication. The analysis was limited to 170 children of self-
reported non-hispanic white ancestry randomized to daily, inhaled
budesonide treatment, on whom lung function (forced expiratory
volume in one second (FEV1)) had been measured before and after
two months of corticosteroid treatment. We found suggestive
associations between the TNC cis-variants and response to inhaled
corticosteroid (rs955387-A, beta=26.99, P=0.005; rs10982634-
C, beta=26.01, P=0.01; rs10817727-G, beta=25.78, P=0.02;
rs12380804-A, beta=28.09 P=0.02; rs10982611-G, be-
ta=22.87, P=0.07; rs10817762-C, beta=22.785, P=0.08)
(Figure 6D) although independent replication is needed to confirm
these findings.
Discussion
We have studied how environmental perturbation impacts
genetic cis-regulation of global gene expression in primary human
osteoblasts. To our knowledge, this is the first study exploring the
cis-regulatory landscape in a population panel of human cells
cultured under multiple conditions and time points. Environmen-
tal stimuli included growth factors, cytokines and steroid hormones
known to be relevant to the cell type studied and with previous
known effects on the osteoblast transcriptome [15–21]. The robust
response to treatment was verified both within and across samples
using different expression platforms and clearly showed evidence
of biologically relevant transcript changes such as the significant
down-regulation of the IGF1 signaling pathway following
glucocorticoid stimulation [14]. However, despite the large impact
on the transcriptome by the treatments, we found that only a small
proportion of the identified cis-eQTLs can be considered as true
treatment-specific, indicating that global changes in gene expres-
sion may be governed more by subtle heritable and environmental
effects.
Our experimental design with the inclusion of multiple
independently derived cell lines as biological replicates improved
not only the detection of response genes but also the discovery of
treatment-specific and treatment-independent cis-eQTLs. We
have previously shown that by including such replicates,
approximately 60% more cis-eQTLs can be identified compared
to the use of single replicates [7]. Using this design in multiple
conditions, we identified ,40% more cis-eQTLs in conditioned
samples as compared to untreated controls but interestingly, when
we compared them across treatments we found that the majority
(.90%) of them were seen in more than one condition. These
findings were confirmed in a slightly different study design
separating the biological replicates and performing two indepen-
dent cis-eQTL analyses per treatment. This indicates that
environmental perturbation seems to allow a higher discovery
rate of genetic cis-effects not because of treatment-specific
regulatory variants but rather due to increased power in cis-eQTL
analysis in conditioning cells, perhaps attributable to a higher level
of coordination of gene regulatory activity between treatments (i.e.
reducing environmental variability of ‘‘resting cell culture’’).
In contrast to environmental-dependence, cell-type specific cis-
regulation of gene expression has previously been studied with
contrasting results. Using human primary fibroblasts and immor-
talized B-lymphocytes, Lee et al [11] found that up to 10% of the
genes studied might be influenced by tissue-specific cis-regulatory
variants whereas Dimas et al [4] reported that 69–80% of
regulatory variants operate in a cell type-specific manner using
similar human cell panels. Notably, the former study utilized AE
monitoring and the latter applied eQTL-mapping. Lee et al [11]
also explored how cis-regulation is affected by experimental
conditions following iPS reprogramming, and their results
indicated that allele-specific expression remained largely invari-
able. Our results are consistent with the more conservative
estimates of context specificity of cis-regulatory variation reported
by others [11,28]. In line with this are the recent observations
indicating that at genome-wide level, trans-variants predominate
when hypothesis free mapping of perturbation specific effects are
mapped [12,13,29]. Based on our earlier results [7], we chose not
to pursue analyses including trans variants, since even among
biological replicates these cannot be reproduced in the current
sample size.
However, we followed-up and validated our findings from the
cis-eQTL analysis by measuring global allele-specific expression
pattern in the different conditioned cells. This allowed us to study
treatment-specific cis-effects in more detail due to higher sensitivity
and specificity of the approach [26]. We were able to validate
,45% of the cis-regulatory effects identified in the eQTL analysis
which is in fact similar to what has been shown previously
comparing AE mapping with traditional cis-eQTL mapping [26].
The reason for the remaining 55% of the cis-eQTL not being
between individuals upon DEX treatment. The Pearson R is considerably lower than for within sample comparisons indicating that most of the AE
variation between individuals is driven by determinants shared between these cells and independent of treatment. (C) Interindividual, treatment
dependent variation in AE (right panel). A total of 159,926 identical informative three SNP windows were available for correlating DEX treatment to
any of the three other treatments between individuals. Correlations between individuals across treatments are not significantly different from within
treatment correlation between individuals shown in (B), indicating that the treatment specific effects observed within individual (A) are sufficiently
weak to be globally unnoticeable due to much stronger correlation of AE to interindividual differences.
doi:10.1371/journal.pgen.1001279.g005
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PLoS Genetics | www.plosgenetics.org 10 January 2011 | Volume 7 | Issue 1 | e1001279validated can be due to insufficient power in AE test, false positives
in eQTL mapping, or measurement of mRNA versus pre-mRNA
in eQTL and AE studies, respectively. Nevertheless, the results
from these allele-specific expression assessments confirmed our
previous findings from eQTL analysis and strengthened the
hypothesis that a large proportion of cis-regulatory variants are
shared across treatments. In fact, the majority of the environmen-
tal-dependent regulatory variants that were identified in eQTL
analysis were shown to be shared across multiple treatments. The
reason for these numerous false-negatives could be explained by
the sensitivity of the eQTL approach where identification of cis-
regulation of low expression transcripts is challenging. An example
of this occurrence is the cis-acting variant regulating the expression
of TNFSF4 that has been associated with susceptibility to systemic
lupus erythematosus and whose cis-regulatory effect is largely
pronounced in activated cells as compared to non-activated cells
due to up-regulation of TNFSF4 expression upon activation [30].
In addition to validating our findings from cis-eQTL analysis,
we used the AE assessments to try and further detect environ-
mental-dependent cis-regulatory effects, focusing on the DEX
treatment. DEX is a synthetic glucocorticoid steroid hormone that
regulates gene expression through binding to its nuclear receptor,
the glucocorticoid receptor (GR). The ligand-receptor complex
binds the DNA at specific glucocorticoid response elements (GRE)
resulting in activation or repression of gene expression [31]. Here,
we were able to detect on average ,60 genes/sample with
evidence of DEX-specific AE differences enriched among DEX-
responsive genes (i.e. showed a significant .1.5-fold difference in
expression upon DEX stimulation) allowing us to speculate
whether the causative eSNP may affect the GR-GRE binding
and subsequent the DEX-GR ability to regulate gene expression.
Recently a comprehensive ChIP-seq study was presented of DEX-
GR binding and its effect on gene expression throughout the
human genome [32]. Reddy et al showed that while genes
activated with DEX treatment have GR bound in proximity to the
TSS, genes repressed with DEX treatment have GR bound
.100kb from the TSS. Moreover, another striking difference
between genes activated and repressed by DEX was the time
required for gene expression response to DEX with repression
beginning much later than activation following DEX exposure.
Interestingly, these features were seen for our top significant DEX-
specific cis-regulated locus, the Tenascin-C (TNC) locus. Tenascin-
C is an extracellular matrix protein whose expression is up-
regulated in inflammatory conditions, such as rheumatoid arthritis
[33] and asthma [27] and known to be down-regulated by DEX
[27,34]. Here we showed that the DEX-specific down-regulation
of TNC is both genotype- and time-dependent with a significant
cis-regulatory effect seen only after the later time point of DEX
exposure and with the top SNP being located ,250 kb upstream
of the TSS. In fact, the same region on chromosome 9 was
identified by ChIP-seq to be bound by GR in human A549 lung
epithelial carcinoma in response to DEX treatment [32].
In conclusion, our results indicate that qualitative (‘‘on/off’’)
interactions between controlled environmental perturbation and
heritable cis-regulatory SNPs are uncommon. Therefore, uncov-
ering true interactions requires either multi-pronged approaches
where independent tools are used to assess treatment specificity on
genetically controlled expression, as employed here. Alternatively,
larger sample sizes with adequate replication in independent
cohorts are required for establishing cis-regulatory variant –
environment interaction, due to much smaller effect sizes than
those observed for natural variation in gene expression among
populations. At the same time, the existence of validated,
genetically controlled, treatment cis-specific effects shown here
suggests that systematic functional genomic screens may yield a
valuable alternative approach for identifying pharmacogenomic
biomarkers altering gene regulation [35], often difficult to access in
clinical cohorts due to limited sample sizes.
Methods
Ethics statement
All research involving human participants have been approved
by institutional review boards (Dnr Ups 03-561, McGill IRB A10-
M121-06B) and conducted according to the principles expressed
in the Declaration of Helsinki.
Primary cell culture
Human trabecular bone from the proximal femoral shaft was
collected from 113 donors (51 female and 62 male donors,
respectively) undergoing total hip or knee replacement at the
Uppsala University Hospital, Uppsala, Sweden. The bone samples
from each donor were thoroughly minced and cultured in three
biological replicates. The cells were grown in medium containing
a-MEM (SigmaAldrich, Suffolk, UK) supplemented with 2 mmol/
l L-Glutamine, 100U/mL penicillin, 100mg/mL streptomycin
(National Veterinary Institute of Sweden, Uppsala, Sweden), and
10% fetal bovine serum (SigmaAldrich, Suffolk, UK) at 37uC with
5% CO2. At 70–80% confluence, the cells were passaged and sub-
cultured in 6-well plates (100,000 cells/well) for 12 days. The
Figure 6. Time-dependent effect of DEX on TNC allelic expression. (A) DEX-specific cis-regulation of the Tenascin-C (TNC) gene located on
chromosome 9 was identified in genome-wide allelic expression (AE) tests by assessing differences in RNA allele ratios at heterozygous sites
normalized to genomic DNA allele ratios (Dhet ratio) across the transcripts. The Dhet ratio from AE tests are shown as vertical bars for untreated
(black, 1
st track), BMP-2 (black, 2
nd track), PGE2 (black, 3
rd track) and DEX (red) treated samples. The direction of effect (+/2) is based on phased
genotype data in the shown individual and marked deviations from equal expression (Dhet ratio=0) are observed only in DEX treated (red) sample,
which predominantly occur in same allele based on statistical phasing. The relatively overexpressed chromosome in this individual harbors the allele
expected to be overexpressed based on population eQTL data (see panel C). (B) The DEX-specific cis-effect of the TNC locus was validated by
sequencing-based AE test in samples heterozygous for the rs13321 exonic marker. Normalized heterozygote allele ratios of RNA samples from DEX
(24h), BMP-2 (2h) and PGE2 (24h) treated cells were compared within and between samples and data are presented as mean 6 SD of three technical
replicates. In 6/8 DEX-treated samples (red), normalized allele ratio deviated greater than 2SD from genomic DNA heterozygote ratio. Significant P-
value (P=2.6610
23) was obtained from t-test comparing normalized allele ratio in DEX versus BMP-2 (blue) and PGE2 (green) samples. Sequencing-
based AE test was then repeated in five DEX-treated samples at the earlier time point (2h) but no deviation from genomic DNA heterozygote ratio
was shown. Significant P-value (P=7.1610
25) was obtained from t-test comparing normalized allele ratio in DEX 24h (red) versus 2h (blue) samples.
(C) cis-eQTL analysis of the TNC locus was performed using genes expression scores IlluminaRef8 array (N=101). The P-values from the linear
regression analysis represented as 2log10(P-value) are shown as vertical bars with a horizontal line indicating a cutoff of P=0.05. The top SNP
rs7850103 (P=2.3610
27) is marked in the figure. (D) SNPs (n=6) in the TNC candidate region were associated with response to inhaled corticosteroid
treatment in 170 children with mild-to-moderate persistent asthma. The P-values from the linear regression analysis represented as 2log10(P-value)
are shown as vertical bars with a horizontal line indicating a cutoff of P=0.05. (E) The HapMap PhaseII CEU LD blocks are shown as a diamond-shaped
plot using log odds (LOD) measures.
doi:10.1371/journal.pgen.1001279.g006
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cells were starved for 20h by adding complete cell medium
containing 0.5% fetal bovine serum. The cells were then incubated
for 2h and 24h with 0.1 mg/ml of rhBMP-2, 100 nM of
dexamethasone, 100 nM of IGF-1, 1mM of PGE2, 100 nM of
PTH (1–34), 0.1 nM of TNF-a, 100 nM of 1.25 VitD3 and with
the same concentration of control, respectively (Table S16). At the
two time points, the cell medium was removed and the cells were
harvested by adding 600mL of RLT buffer (Qiagen, GmbH,
Germany). The cell lysates were homogenized by using QIAsh-
redder (Qiagen, GmbH, Germany) homogenizers and stored in
270uC until RNA extraction.
The study was approved by the local ethics committees (Dnr
Ups 03-561, McGill IRB A10-M121-06B).
RNA extraction
RNA was extracted from cell lysates using the RNeasy Mini Kit
(Qiagen, Mississauga, Canada). High RNA quality was confirmed
for all samples using the Agilent 2100 BioAnalyzer (Agilent
technologies, Palo Alto, CA, USA) and the concentrations were
determined using NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA).
Expression profiling—Affymetrix GeneChip
Expression profiling of one complete sample was performed in
triplicate (biological replicates) using the Affymetrix Human
Genome U133 plus 2.0 Array (Affymetrix, Santa Clara, CA,
USA). One microgram of RNA was reverse transcribed into
cDNA and in vitro transcription was performed to generate biotin-
labeled cRNA for subsequent hybridization. Hybridized target
cRNA was then stained with streptavidin phycoerythrin, and
arrays were scanned using a GeneArray Scanner at an excitation
wavelength of 488nm. The raw data was imported to BioCon-
ductor [36] using the R 2.5.0 package and normalized mean
expression values were generated by the Robust Multichip
Average algorithm [37,38].
The microarray data have been deposited in the Gene
Expression Omnibus (GEO), www.ncbi.nlm.nih.gov/geo (acces-
sion no. GSE10311).
Expression profiling—Illumina BeadChips
Expression profiling of one complete sample and of all BMP-2
(2h, n=101), dexamethasone (24h, n=106), PGE2 (24h, n=105)
and untreated control (24h, n=95) samples, each with at least two
biological replicates, was performed using the Illumina HumRef-
8v2 BeadChips (Illumina Inc. San Diego, CA, US) where 200ng of
total RNA was processed according to the protocol supplied by
Illumina. The raw data was imported to BioConductor [36] using
the R 2.5.0 lumi package for variance-stabilizing transformation
and robust spline normalization to obtain normalized mean
expression values. The detectionCall algorithm in the lumi
package was used to find genes uniquely expressed in one
condition. A gene was considered expressed if present in at least
10% of the measured samples.
The microarray data has been deposited in the Gene Expression
Omnibus (GEO), www.ncbi.nlm.nih.gov/geo (accession no. GSE
15678, GSE21410, GSE21725, GSE21726, GSE21727).
Gene network and pathway analysis
In order to visualize whole-genome expression data in the
context of biological networks, functions or pathways data were
analyzed through the use of Ingenuity Pathway Analysis (IPA)
system (Ingenuity Systems, Mountain View, CA, USA, www.
ingenuity.com). The datasets containing differently expressed
genes (FDR adjusted P,0.05 and Fold change .2) or genes
harboring a treatment-specific cis-eQTL were uploaded to the
application. Each gene identifier was mapped to its corresponding
gene object in the Ingenuity Pathways Knowledge Base. A fold
change cutoff was set to identify genes whose expression was
significantly differentially up or down-regulated. These genes,
called Focus Genes, were overlaid onto a global molecular
network developed from information contained in the Ingenuity
Pathways Knowledge Base. Networks of these Focus Genes were
then algorithmically generated based on their connectivity.
The Functional Analysis identified the biological functions that
were most significant to the dataset. Genes from the dataset that
met the cutoff and were associated with biological functions in the
Ingenuity Pathways Knowledge Base were considered for the
analysis. Fisher’s exact test was used to calculate a p-value
determining the probability that each biological function assigned
to the dataset is due to chance only.
Assessment of differently expressed genes
The Cyber-t test was used to determine the significance between
the observed differences in gene expression. The Cyber-t test is
based on simple t-tests and uses the observed variance of gene
measurements across replicate experiments, thereby accommo-
dating noise, variability, and low replication, often typical of
microarray data [39]. Since the number of tests (genes) is large, the
p-values are adjusted for multiple comparisons using the false
discovery rate (FDR) algorithm [40] in Bioconductor using the R
2.5.0-package [36].
For the proportion of differentially expressed genes among all
tested genes for each treatment (1-pi0) the qvalue package
implemented in R was used [40].
DNA extraction
DNA was successfully extracted from cell lysates of 109/113
samples and re-suspended in 200ml PBS using the GenElute DNA
Miniprep Kit (SigmaAldrich, Suffolk, UK). Concentrations were
determined using the Quant-iT PicoGreen kit (Molecular Probes).
Whole-genome genotyping
Genotyping was performed on 106 samples using the Illumina
HapMap 550k Duo chip (Illumina Inc., San Diego, CA, US)
according to the protocol provided by the manufacturer. The total
number of SNPs included on the chip is 561,303. Individuals with
low genotyping rate (,90%) and SNPs showing significant
deviation from Hardy-Weinberg equilibrium (P,0.05) were
excluded. Similarly, low frequency SNPs (MAF,0.10) and SNPs
with high rates of missing data (.5%) were excluded. The average
success rate of the genotyping of the 561,303 SNPs across all
individuals was 99%.
Genotype–phenotype association analysis
Of the 22,184 Illumina probes (corresponding to 18,144 genes),
those with SNPs (dbSNP build 126) within them were excluded.
We tested for association of the induced expression levels to SNPs
using the linear regression model implemented in the PLINK
software (http://pngu.mgh.harvard.edu/purcell/plink/) [41] as-
suming additive effect of the SNPs. Two covariates were also
included in the regression model; year of birth and sex
(mRNA=a+b1SNP1+b2cov12+b3cov23+e). Cis-regulatory effects
were tested using SNPs mapping 6250kb flanking the gene or
within the gene itself. In order to study whether array
hybridization time point (i.e. batch) biased our data and masked
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batch as a cofactor in exactly overlapping samples across
treatments (n=80) keeping the biological replicates separate in
independent cis-eQTL analyses.
We also analyzed the data sets jointly by fitting a linear mixed
model using the SAS 9.1 software (SAS institute Inc., Cary, NC,
US). Treatment group was included as a random effect and year of
birth and sex as fixed effects. Two interactions terms were also
included; treatment*SNP and sex*SNP, respectively. No signifi-
cant sex*SNP interaction effects were found.
Independent cis-eQTLs were identified by first obtaining
genome-wide recombination hotspot coordinates based on the
HapMap Phase 2 (release 22, NCBI 36) data (http://hapmap.
ncbi.nlm.nih.gov/downloads/recombination). Within each locus
we first identified top associations within each interval between
recombination hotspots and retained the top ranking association.
Next we tested for potential residual LD (D9.0.5) between
significant associations mapping to independent recombination
hotspot intervals in our population using our genotyping as input
in the Haploview software (version 4.2) (www.broadinstitute.org/
haploview). Only the top association from SNPs showing
pairwise D9.0.5 was kept for each locus to identify unique
cis-eQTLs.
Genotype imputation
Genotypes from 103 samples that passed quality control were
imputed for all SNPs (n=478,805) oriented to the positive strand
from phased (autosomal) chromosomes of the HapMap CEU
Phase II panel (release 22, build 36). Untyped markers were
inferred using algorithms implemented in MACH 1.0 [42,43]. R
2
was used as imputation quality control metrics and estimates the
squared correlation between imputed and true genotypes. A cut-
off of R
2,0.3 was used to remove poorly imputed markers.
Association of imputed genotypes using estimated genotype
probabilities with expression traits was performed using a linear
regression model implemented in the MACH2QTL software [42–
44] with sex and year of birth as covariates.
The genomic DNA data collected in parallel from 1.1 M SNPs
in these individuals also allowed us to measure imputation
accuracy across the dataset using a common set of 636,676 SNPs.
Overall, 88% of the HapMap SNPs were imputed at 100%
accuracy across samples and the error rate within a sample was
3% which is similar to what has been reported previously [45].
Primer design
Primers were designed using the Primer3 v. 0.4.0 software
(http://frodo.wi.mit.edu/) and all primer sequences can be found
in Table S17.
Sequencing-based AE analysis
Allele-specific expression was assessed by quantitative sequenc-
ing [24]. High-quality RNA was used to synthesize first strand
cDNA with random hexamers (Invitrogen, Burlington, Canada)
and Superscript II reverse transcriptase (Invitrogen, Burlington,
Canada). For each locus, we designed exonic primers and we used
PeakPicker v.2.115 with the default settings to quantify the relative
amount of the two alleles at the heterozygote site measured from
the chromatogram after peak intensity normalization. The
normalized heterozygote ratios of genomic DNA samples were
used to calculate mean and SD for each SNP. If all heterozygote
ratios from three technical replicates showed concordant deviation
greater than two SDs from the genomic DNA heterozygote ratio
mean, the sample was called to have allele-specific expression.
Retroviral transduction of primary osteoblasts
The PA317-neo packaging cells (ATCC Inc, Manassas, VA,
US) expressing pLXSN hTERT and pLXSN HPV16-E7 were
kindly provided by Dr Eric Shoubridge (McGill University,
Montreal, QC, CA). The packaging cells were grown to near
confluence in DMEM containing 10% FBS (SigmaAldrich,
Suffolk, UK). After 24 h to 48h, the medium containing retroviral
particles was harvested and filtered through a 0.45-mm filter and
mixed with complete cell medium. Polybrene was added to a final
concentration of 4ug/mL.
Five of the cultured human osteoblast lines (see above) were
plated in 75-cm
2 culture flasks and cultured in a-MEM
(SigmaAldrich, Suffolk, UK) supplemented with 2 mmol/l L-
Glutamine, and 10% fetal bovine serum (SigmaAldrich, Suffolk,
UK). When cells reached 30–40% confluence, the media were
removed and 6 ml of fresh prepared retroviral suspension (1.5 ml
of hTERT suspension, and 1.5 ml of E7 suspension and 3 ml of
medium, respectively) was added to the cells and incubated 1–
2 hours at 37uC. Growth medium was then added with polybrene
to bring up to usual flask volume and maintain incubating
overnight at 37uC. The media were then removed and the cells
were rinsed once with fresh medium and new culture medium
without polybrene was added. After 48h, the media were changed
to selection media containing 400mg/ml of G418 (Invitrogen,
Burlington, ON, CA) and the cells were cultured under these
selection conditions for 2–3 weeks.
The immortalized osteoblasts were seeded in 75-cm
2 and
cultured in complete cell medium. At 80% confluence, the cells
were starved for 20h by adding complete cell medium containing
0.5% fetal bovine serum (SigmaAldrich, Suffolk, UK). The cells
were then incubated with 10
24 mg/ml of rhBMP-2 (2h), 10
27 M
of dexamethasone (24h) and 10
26 M of PGE2 (24h) and with the
same concentration of control, respectively. At the different time
points, the cell medium was removed and the cells were harvested
by adding 2mL of TRIzol Reagent (Invitrogen, Burlington, ON,
CA) and stored in 270uC until RNA extraction.
Robust responses to each treatment of these newly cultured cells
were confirmed by comparison of gene expression assessed by real-
time RT-PCR experiments in both immortalized and the
corresponding primary treated HObs, respectively. Genes validat-
ed were selected from expression profiling using the Illumina Ref8
Beadarrays of primary cells.
Real-time RT-PCR
Aliquots of the different RNA from the primary or immortalized
cell, respectively, were each annealed to 500 ng of random
hexamers (Invitrogen Corporation, Carlsbad, CA, USA) at 70uC
in 10 min. First-strand cDNA synthesis was performed using
SuperScript II reverse transcriptase (Invitrogen Corporation,
Carlsbad, CA, USA) according to manufacturer’s instructions.
The target gene as well as the 18S housekeeping gene were
analyzed in triplicates as well as a calibration curve from a two-
fold dilution series of control cDNA and non-template control
(NTC) samples. The real-time PCR assays were performed on the
Rotor-Gene
TM 6000 real-time rotary analyzer (Corbett Life
Sciences, Sydney, Australia) using the Platinum SYBR Green
qPCR SuperMix-UDG (Invitrogen Corporation, Carlsbad, CA,
USA) according to manufacturer’s recommendation. The cycling
conditions on the Rotor-Gene
TM 6000 real-time rotary analyzer
were: 4 minutes at 95uC, 40 cycles x (20 seconds at 95uC,
30 seconds at 58uC and 30 seconds at 72uC) followed by the
dissociation protocol at 72uC.
Results of the experimental samples were analyzed using the
comparative CT method. The CT mean and standard deviation
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mean CT value was then normalized to the 18S mean CT value.
All statistical analyses for the associations of delta CT values with
genetic variants were performed using a general linear model in
SAS 9.1 (SAS institute Inc., Cary, NC, US).
RNA and DNA preparation for Illumina Human omni1-
quad BeadArrays
Approximately 150mg of total RNA was extracted from the cells
using the commercially available TRIzol reagent protocol
(Invitrogen, Burlington, ON, CA) and subsequently treated with
18 U DNaseI (Ambion Inc., Austin, TX, USA) for 30 min at 37uC
and further extracted with phenol/chloroform. High RNA quality
was confirmed for all samples using the Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA, USA) and the concentra-
tions were determined using the NanoDrop ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA). Poly(A) RNA was then
isolated using the MicroPoly(A)Purist protocol (Ambion Inc.,
Austin, Tx, USA) and poly-A enriched RNA quality and quantity
was measured using the Agilent 2100 BioAnalyzer and NanoDrop
ND-1000, respectively.
DNA from the cell lysates was extracted using the GenElute
DNA Miniprep Kit (SigmaAldrich) according to the protocol
provided by the manufacturer and concentrations were deter-
mined using the NanoDrop ND-1000.
First- and second-strand cDNA synthesis
Approximately 1mg poly-A enriched RNA was annealed to 50ng
of random hexamers (Invitrogen, Burlington, ON, CA) at 70uC for
10 min. First- and second strand cDNA synthesis was performed
using the Superscript Double-Stranded cDNA Synthesis Kit
(Invitrogen, Burlington, ON, CA) according to the manufacturer’s
instructions. The double-stranded cDNA was extracted with
phenol:chloroform:isoamyl alcohol and dissolved in 12ul DEPC-
treated water. The size distribution of the double-stranded cDNA
samples (average 1.2–1.5kb) was confirmed using the Agilent
BioAnalyzer DNA Kit.
Genotyping and AE analysis on Illumina Human omni1-
quad BeadChips
Approximately 200ng of genomic DNA and 50–300ng double-
stranded cDNA sample was used for the parallel genotyping and
AE analysis on the Illumina Infinium Omni1-Quad BeadArrays
according to the manufacturer’s instructions (Illumina Inc., San
Diego, CA, US). Genotypes in genomic DNA were extracted using
BeadStudio. The parallel assessment of genomic DNA and cDNA
heterozygote ratios was carried out essentially as described earlier
[26], but signal intensity normalization at heterozygous sites
followed a slightly modified approach. For AE analysis we utilized
the Xraw and Yraw signal intensities and since the variances in the
two channels are not same (i.e. it is a function of total intensity
from both channels) we need to correct this variation through
normalization to allow comparison between gDNA and cDNA
allele ratios. In this study, we only normalized b ratio (Xraw/
(Xraw+Yraw)) from heterozygous SNPs with total intensity (Xraw
+Yraw) higher than the threshold value of 3000. The scatter plot of
b ratio against the logarithm 10 scaled total intensity fits well with
polynomial regression model (quadratic regression model). This
model shows better fitting than linear regression model we
employed earlier for normalization [26], which works well in
higher intensity part, but poor in lower intensity part in many
samples. The normalization process can be briefly summarized to
following steps: 1) The b ratio is calculated along with total
intensity in log10 scale for all heterozygous SNPs. 2) All data
points with greater than 3000 in total intensity are divided into 50
intensity bins. 3) A fitted curve from the median b ratio in each bin
is computed using a polynomial regression model (quadratic
regression) y=b1x+b2x
2+a where y is expected b ratio from the
curve and x is log10 scaled total intensity. 4) From the fitted curve,
the expected b ratio based on total intensity calculated. 5) The
final normalized b ratio equals (bobs2bexpected+0.5). Following
normalization, all median b ratio values in all intensity bins should
be close, if not equal, to 0.5.
Empirical probabilities for observing differences in AE for
transcripts were assessed by first observing the genome-wide
distribution of AE-magnitude at expressed heterozygous sites
[Dhet ratio=X DNA/(XDNA+YDNA)2XRNA/(XRNA+YRNA)]. The
use of AE magnitude alone allows us to do the comparisons in
unphased chromosomes, which we chose to use as a global test since
statistical phasing introduces potential errors. However, in case of
TNC (Figure 6A), we used derived phased [46] data to show that
significant biases at individual sites are observed for the same
expressed allele. We defined three SNP expressed windows by
requiring that at least three of four consecutive heterozygous sites
showed signal above threshold. We note that in comparison across
treatments, we used only multi-SNP windows that were above signal
threshold in all treatments within an individual. This restricted the
analysis to 6791/8097 informative RefSeq genes and captured all
informativegenes (n=2880) showingabove medianexpression scores
based on Illumina Ref-8 data used in eQTL analysis. Multiplicative
likelihood of observing three consecutive SNPs with high Dhet ratio
magnitude was compared to 5
th percentile of multiplicative likelihood
in randomly permuted data from same sample. The same process
was used in assessing empirical probability of observing DEX-
specific changes in allelic expression, except that direction of effect
(greater or lower DDexa het ratio) was taken into account for the three
consecutive SNPs and we applied the following formula to calculate
DDex het ratio=X RNA_DEX/(XRNA_DEX+YRNA_DEX)2XRNA_OTHER/
(XRNA_OTHER+YRNA_OTHER). The gene-based false discovery rate
(FDR) of DEX-specific AE was also empirically assessed for each
sample using RefSeq annotated genes where multiple three SNP
windows had been independently measured for same transcript and
the empirical FDR represents the proportion of discordant calls
among all genes from same sample.
CAMP cohort association analyses
Association between TNC SNPs and clinical response to inhaled
corticosteroids was performed using information from subjects
participating in the Childhood Asthma Management Program
(CAMP). CAMP is a multicenter, randomized, double-blind,
placebo-controlled trial to investigate the long-term effects of
inhaled anti-inflammatory medication (budesonide 200 mg twice
daily or nedocromil 8 mg twice daily both versus placebo) in
children 5 to 12 years of age. 1,041 asthmatic children were
followed for a mean 4.6 years. Trial design and primary outcomes
have been published [47]. Individuals were randomized to
budesonide, nedocromil, or placebo. Of the non-Hispanic white
CAMP probands randomized to inhaled corticosteroids, 118
subjects and their parents were genotyped on the Illumina
HumanHap550v3 BeadChip [48], with an additional 52 trios
genotyped on the Illumina Human 610-Quad BeadChip. All
CAMP subjects provided assent and their legal guardians consent
to study protocols and ancillary genetic testing. The two month
change in FEV1 in response to inhaled corticosteroids was
calculated as previously described and was shown to be normally
distributed [49]. Association between TNC SNPs common to both
genotyping platforms and inhaled steroid response was calculated
cis-Regulation of Induced Gene Expression
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adjusted for non-genetic covariates including sex, height and age.
Supporting Information
Figure S1 Global response on gene expression upon environ-
mental perturbation. The significance of the treatment-induced
effects at two time points, 2h (left panel) and 24h (right panel), on
the global gene expression assessed by AffymetrixU133+2 arrays
(A) and IlluminaRef8 beadarrays (B) in two individuals, respec-
tively, was determined by the Cyber-t test using three biological
replicates in 1.25VitD3 (top), IGF-1 and PTH (middle) and PGE2
(bottom) treated versus control samples, respectively. PTH failed
in IlluminaRef8 expression profiling experiment and thus not
included in (B). The results from the statistical tests are combined
with the magnitude of the change in gene expression following
perturbation and visualized in Volcano plots with significance
(2log2 P value) versus fold change (log2) on the y – and x-axes,
respectively. Lines indicate genes whose expression levels were
significantly (FDR adjusted P,0.05) changed more than 2-fold.
Found at: doi:doi:10.1371/journal.pgen.1001279.s001 (0.31 MB
PDF)
Figure S2 Validation of PGE2 responsive genes by real-time
RTPCR. The effect of 1mM of PGE2 on gene expression in
primary human trabecular bone cells was verified by quantitative
real-time (RT) PCR. The same sources of total RNA used in the
microarray experiments were used for the data validation. For
each gene in the RT-PCR assay, the three biological replicates
were analyzed in duplicates and normalized to the 18s mean value.
The fold changes between control samples (grey bars) and PGE2
induced samples (black bars) were calculated using the relative
standard curve method. Data are presented as mean and standard
deviation.
Found at: doi:doi:10.1371/journal.pgen.1001279.s002 (0.05 MB
PDF)
Figure S3 Correlation of expression changes upon treatment
between experiments. The expression changes upon BMP-2,
dexamethasone and PGE2 treatment assessed by Affymetrix
U133+2 arrays was verified in the whole study population using
Illumina HumanRef8 v2 arrays. In total of 13,030 RefSeq genes
overlapped the two studies and expression changes of those genes
were included in correlation analysis. Fold changes (log2) were
calculated using three biological replicates of a single sample from
Affymetrix U133+2 arrays and plotted on the y-axis against
median fold changes (log2) in the whole study population using
Illumina HumanRef8 v2 arrays on the x-axis.
Found at: doi:doi:10.1371/journal.pgen.1001279.s003 (1.30 MB
PDF)
Figure S4 Proportion of the variability accounted for by the cis-
variants. Graphical representation of the proportion of the total
variance (R
2, x-axis) explained by each independent cis-eSNP at
5% FDR. Total number of significant cis-eQTLs were 1121 (A-
untreated samples), 1281 (B-DEX-treated samples), 1571 (C-BMP-
2-treated samples) and 1571 (D-PGE2-treated samples), respec-
tively.
Found at: doi:doi:10.1371/journal.pgen.1001279.s004 (0.08 MB
PDF)
Figure S5 Distribution of independent cis-eQTLs around TSS.
Graphical representation of the distance (kb, x-axis) of each
independent cis-association (5% FDR) relative to the transcription
start site (TSS). Total number of significant cis-eQTLs were 1121
(A-untreated samples), 1281 (B-DEX-treated samples), 1571
(C-BMP-2-treated samples) and 1571 (D-PGE2-treated samples),
respectively.
Found at: doi:doi:10.1371/journal.pgen.1001279.s005 (0.07 MB
PDF)
Figure S6 P-value distribution of treatment-specific eQTLs.
Significant dexamethasone-specific cis-eQTLs at 1% FDR
(n=3485) were selected and the distribution of corresponding P-
value from cis-eQTL analysis in BMP-2 (A), PGE2 (B) and
untreated samples (C) were displayed in a histogram where
tabulated frequencies of cis-eQTLs at each P-value interval are
shown as bars.
Found at: doi:doi:10.1371/journal.pgen.1001279.s006 (0.09 MB
PDF)
Figure S7 Validated treatment-specific effect on cis-regulation
of gene expression. The expression differences in AA versus BB
samples (log2 fold change, y-axis) were compared between
validated treatment-specific (n=5, group 1–2) and treatment-
independent (n=68, group 3–4) loci. Group 1 and 3 represent
genotype-dependent effect by a specific treatment (BMP-2,
dexamethasone or PGE2) identified in cis-eQTL analysis and
group 2 and 4 of the averaged effect of the three corresponding
treatments for each specific locus, respectively. Results are
presented in box plots with a horizontal line in each box
representing the median.
Found at: doi:doi:10.1371/journal.pgen.1001279.s007 (0.06 MB
TIF)
Figure S8 Time-dependent effect of DEX on TNC allelic
expression. Normalized TNC expression (deltaCT) in untreated
(P=0.5) and DEX-treated samples (P=3.7610
24) (left and
middle) as well as the fold change (P=3.7610
24) (right) was
associated with TNC rs7859920 genotypes in a linear regression
model.
Found at: doi:doi:10.1371/journal.pgen.1001279.s008 (0.92 MB
EPS)
Table S1 Proportions of differently expressed genes (1-pi0) using
Storey’s q value.
Found at: doi:doi:10.1371/journal.pgen.1001279.s009 (0.02 MB
XLS)
Table S2 Response genes following DEX stimulation for 24h.
Found at: doi:doi:10.1371/journal.pgen.1001279.s010 (3.73 MB
XLS)
Table S3 Response genes following BMP-2 stimulation for 2h.
Found at: doi:doi:10.1371/journal.pgen.1001279.s011 (3.73 MB
XLS)
Table S4 Response genes following PGE2 stimulation for 24h.
Found at: doi:doi:10.1371/journal.pgen.1001279.s012 (3.73 MB
XLS)
Table S5 Summary of results from two independent cis-eQTL
analyses separating the biological replicates.
Found at: doi:doi:10.1371/journal.pgen.1001279.s013 (0.02 MB
XLS)
Table S6 Summary of independent cis-eQTLs at 5% FDR.
Found at: doi:doi:10.1371/journal.pgen.1001279.s014 (0.89 MB
XLS)
Table S7 DEX-specific cis-eQTLs at 5% FDR.
Found at: doi:doi:10.1371/journal.pgen.1001279.s015 (0.34 MB
XLS)
Table S8 BMP-2-specific cis-eQTLs at 5% FDR.
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XLS)
Table S9 PGE2-specific cis-eQTLs at 5% FDR.
Found at: doi:doi:10.1371/journal.pgen.1001279.s017 (0.09 MB
XLS)
Table S10 Gene enrichment analysis.
Found at: doi:doi:10.1371/journal.pgen.1001279.s018 (0.03 MB
XLS)
Table S11 Significant SNP*treatment interactions.
Found at: doi:doi:10.1371/journal.pgen.1001279.s019 (0.06 MB
XLSX)
Table S12 Treatment-specific cis-eQTLs validated in se-
quenced-based AE test.
Found at: doi:doi:10.1371/journal.pgen.1001279.s020 (0.02 MB
XLS)
Table S13 Treatment response in primary versus immortalized
cells.
Found at: doi:doi:10.1371/journal.pgen.1001279.s021 (0.02 MB
XLS)
Table S14 Treatment-specific cis-eQTLs validated in global AE
test.
Found at: doi:doi:10.1371/journal.pgen.1001279.s022 (0.09 MB
XLS)
Table S15 DEX-specific AE.
Found at: doi:doi:10.1371/journal.pgen.1001279.s023 (0.03 MB
XLS)
Table S16 Description of treatment panel.
Found at: doi:doi:10.1371/journal.pgen.1001279.s024 (0.03 MB
XLS)
Table S17 Primer sequences.
Found at: doi:doi:10.1371/journal.pgen.1001279.s025 (0.02 MB
XLS)
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